17th treatment shown to reduce risk in
March 2021, now with p = 0.00036 from 31 studies, recognized in 45 countries.
Efficacy is variant dependent.
No treatment is 100% effective. Protocols
combine treatments.
5,100+ studies for
112 treatments. c19early.org
|
risk of symptomatic case, 93.6% lower, RR 0.06, p = 0.009, treatment 0 of 186 (0.0%), control 8 of 223 (3.6%), NNT 28, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
|
risk of case, 47.9% lower, RR 0.52, p = 0.07, treatment 10 of 186 (5.4%), control 23 of 223 (10.3%), NNT 20.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |